WINTON GROUP Ltd - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 97 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
WINTON GROUP Ltd ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2021$158,000
+3.3%
62,869
+17.3%
0.01%
+12.5%
Q2 2021$153,000
+48.5%
53,609
+21.8%
0.01%
+33.3%
Q1 2021$103,000
+68.9%
44,013
+26.6%
0.01%
+50.0%
Q4 2020$61,000
-3.2%
34,771
-48.5%
0.00%
+100.0%
Q3 2020$63,000
-33.0%
67,532
-37.6%
0.00%0.0%
Q2 2020$94,000
-4.1%
108,280
-9.0%
0.00%
-33.3%
Q1 2020$98,000
-31.0%
118,935
-25.4%
0.00%
+50.0%
Q4 2019$142,000159,3510.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q1 2020
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$55,198,0004.16%
Raffles Associates 1,930,536$3,050,0003.32%
Defender Capital, LLC. 5,131,935$8,108,0003.18%
Prescott General Partners LLC 1,851,851$2,926,0000.20%
DAFNA Capital Management LLC 140,000$221,0000.06%
Laurion Capital Management LP 2,422,367$3,827,0000.06%
Beirne Wealth Consulting Services, LLC 45,000$71,0000.05%
Fort Sheridan Advisors LLC 78,931$125,0000.04%
Long Focus Capital Management, LLC 215,000$340,0000.04%
MORGAN JESS S & CO INC 20,000$32,0000.03%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders